international gastric cancer congress 2022 | MARCH 6 - 9, 2022 | JOIN IN-PERSON OR ONLINE

the evolution of gastric cancer science;
the future of gastric cancer treatment


As a special privilege, IGCA Members have free-access to the Gastric Cancer journal!

Gastric Cancer is an official journal issued jointly with the Japanese Gastric Cancer Association (JGCA). It publishes significant studies related to gastric cancer and had an Impact Factor of 7.370 in 2020.


Gastric Cancer journal is a worldwide forum for surgeons, medical oncologists, epidemiologists, and basic scientists, to investigate problems in gastric cancer.
The journal covers all areas of treatment and biology relevant to gastric cancer, including genetic, biochemical, and cellular aspects.
Browse through a shortlist of highly relevant articles:

Totally laparoscopic gastrectomy (TLG), which involves a complete intracorporeal gastric transection and the creation of an anastomosis, has been gradually adopted.
However, a potential limitation of intracorporeal transection is the lack of tactile feedback, and whether this limitation influences oncological outcomes is unclear. The aim of this study is to evaluate the short- and long-term oncological safety of TLG using endoscopy-guided intracorporeal gastric transection for clinical stage (cStage) I gastric cancer.
To read the full article, click here.

The aim of this study was to identify serum miRNAs that discriminate early gastric cancer (EGC) samples from non-cancer controls using a large cohort. To access the full article, click here.

Surveillance after curative surgery for gastric cancer is conventionally performed for 5 years. However, the appropriate follow-up period remains controversial. For the full results, click here.

For diagnosing gastric cancer, differences in the diagnostic performance between endocytoscopy with narrow-band imaging and magnifying endoscopy with narrow-band imaging have not been reported. We aimed to clarify these differences by analyzing diagnoses made by endoscopists in Japan. Click here to read the full study.

In East Asia, S-1 plus cisplatin (SP) is one of the standard first-line chemotherapy regimens for metastatic or recurrent gastric cancer (MRGC). Oxaliplatin is generally less toxic and more convenient to administer than cisplatin. Read the full article here.

Journal subscription

To access the full journal, you will need a username and password. These details will be sent to you by e-mail after you have renewed or applied for membership.

If you have already received your login details, please click here to access the Gastric Cancer journal.